Calcium and Phosphate Handling — MCQs
In hypoparathyroidism:
Secondary hyperparathyroidism due to Vit D deficiency shows :
Aldosterone mainly acts upon
Which of the following is the primary mechanism that drives sodium reabsorption in the proximal tubule?
What is the initial treatment of choice for managing secondary hyperparathyroidism in patients with renal osteodystrophy?
Which of the following substances is NOT typically found in gallstones?
Technetium-99m methylene diphosphonate is structurally similar to
All of the following statements regarding stones in the submandibular gland are true except one:
The function of which of the following is increased by an elevated parathyroid hormone concentration:
Which of the following is not a treatment option for hypercalcemia?
Calcium and Phosphate Handling Indian Medical PG Practice Questions and MCQs
Question 1: In hypoparathyroidism:
- A. Plasma calcium is high and inorganic phosphorous low
- B. Plasma calcium and inorganic phosphorous are low
- C. Plasma calcium is low and inorganic phosphorous high (Correct Answer)
- D. Plasma calcium and inorganic phosphorous are high
Explanation: ***Plasma calcium is low and inorganic phosphorous high*** - **Hypoparathyroidism** is characterized by insufficient parathyroid hormone (PTH) production, leading to decreased bone resorption and reduced renal reabsorption of calcium [1]. This results in **hypocalcemia** (low plasma calcium) [1]. - PTH also promotes renal excretion of phosphate [2]. With insufficient PTH, renal phosphate excretion is impaired, leading to **hyperphosphatemia** (high inorganic phosphorus) [1]. *Plasma calcium is high and inorganic phosphorous low* - This profile is characteristic of **primary hyperparathyroidism**, where excessive PTH causes increased bone resorption and renal calcium reabsorption (high calcium), and increased renal phosphate excretion (low phosphorus). - It directly contradicts the defining features of hypoparathyroidism [1]. *Plasma calcium and inorganic phosphorous are low* - While plasma calcium is low in hypoparathyroidism, plasma inorganic phosphorus is characteristically high, not low [1]. - A combination of low calcium and low phosphorus can be seen in conditions like **vitamin D deficiency** (osteomalacia), but not directly in pure hypoparathyroidism [1]. *Plasma calcium and inorganic phosphorous are high* - This combination of high calcium and high phosphorus is uncommon and not typically seen in either hypoparathyroidism or hyperparathyroidism. - It could potentially indicate conditions like **milk-alkali syndrome** or **vitamin D intoxication**, but not hypoparathyroidism, which is defined by low calcium [1].
Question 2: Secondary hyperparathyroidism due to Vit D deficiency shows :
- A. Hypocalcemia (Correct Answer)
- B. Hypophosphatemia
- C. Hypercalcemia
- D. Hyperphosphatemia
Explanation: ***Hypocalcemia*** - **Vitamin D deficiency** leads to decreased intestinal absorption of calcium, causing **hypocalcemia** [3]. - This persistent **low serum calcium** is the primary stimulus for the parathyroid glands to increase PTH secretion, leading to secondary hyperparathyroidism [1], [2]. *Hypophosphatemia* - While PTH typically promotes phosphate excretion in the kidneys leading to hypophosphatemia, in **secondary hyperparathyroidism due to vitamin D deficiency**, the effect on phosphate can be variable [3]. - The goal of increased PTH is to raise calcium, and maintaining some level of phosphate is necessary for bone health and proper calcium regulation. Early or mild deficiency may not show significant hypophosphatemia. *Hypercalcemia* - **Hypercalcemia** is a characteristic feature of **primary hyperparathyroidism**, where the parathyroid glands autonomously overproduce PTH [1]. - In secondary hyperparathyroidism (due to vitamin D deficiency), the PTH is elevated in response to **low calcium**, and sustained significant hypercalcemia is not expected; in fact, the underlying problem is **hypocalcemia** [1]. *Hyperphosphatemia* - **PTH** generally acts to lower serum phosphate levels by promoting its renal excretion [2]. - Therefore, **hyperphosphatemia** is not typically observed in secondary hyperparathyroidism; rather, a more common finding would be normal or low phosphate due to the elevated PTH [3].
Question 3: Aldosterone mainly acts upon
- A. Loop of Henle
- B. Distal renal tubule (Correct Answer)
- C. PCT
- D. Glomerulus
Explanation: ***Distal renal tubule*** - Aldosterone primarily acts on the **principal cells** of the **distal convoluted tubule** and collecting duct. - Its main function is to promote **sodium reabsorption** and **potassium excretion** in these segments. *Loop of Henle* - The Loop of Henle is primarily involved in establishing the **medullary osmotic gradient** and reabsorbing water and solutes, but it is **not the primary site** of aldosterone action. - While some sodium is reabsorbed here, this process is largely independent of aldosterone's direct influence. *PCT* - The **proximal convoluted tubule (PCT)** is responsible for the bulk reabsorption of filtered substances, including about 65% of sodium and water. - Aldosterone has **minimal to no direct effect** on the reabsorptive processes occurring in the PCT. *Glomerulus* - The **glomerulus** is the site of **ultrafiltration**, where blood is filtered to form a protein-free filtrate. - Aldosterone has no direct action on the filtration barrier or the cells of the glomerulus.
Question 4: Which of the following is the primary mechanism that drives sodium reabsorption in the proximal tubule?
- A. Sodium reabsorption through cotransport with amino acids at the luminal membrane.
- B. Sodium reabsorption through cotransport with glucose at the luminal membrane.
- C. Sodium reabsorption through countertransport with hydrogen ions at the luminal membrane.
- D. Active sodium transport via the Na+-K+-ATPase pump at the basolateral membrane. (Correct Answer)
Explanation: ***Active sodium transport via the Na+-K+-ATPase pump at the basolateral membrane.*** - This pump **actively transports sodium out of the cell** into the interstitial fluid, creating a low intracellular sodium concentration. - The **Na+-K+-ATPase** is the primary driver of sodium reabsorption throughout the nephron, creating the electrochemical gradient for other sodium transporters. *Sodium reabsorption through cotransport with amino acids at the luminal membrane.* - While **sodium-amino acid cotransport** does occur in the proximal tubule, it accounts for only a fraction of total sodium reabsorption. - The primary driving force for this cotransport is the **low intracellular sodium concentration** maintained by the Na+-K+-ATPase. *Sodium reabsorption through cotransport with glucose at the luminal membrane.* - **Sodium-glucose cotransporters (SGLTs)** are crucial for glucose reabsorption in the proximal tubule, moving glucose into the cell along with sodium. - However, glucose cotransport represents a specific mechanism for glucose handling, not the overarching mechanism for sodium reabsorption. *Sodium reabsorption through countertransport with hydrogen ions at the luminal membrane.* - The **Na+-H+ exchanger (NHE3)** is significant for exchanging sodium for hydrogen ions at the luminal membrane in the proximal tubule. - This mechanism is important for **acid-base balance** and some sodium reabsorption, but it is secondary to the Na+-K+-ATPase in driving the overall sodium gradient.
Question 5: What is the initial treatment of choice for managing secondary hyperparathyroidism in patients with renal osteodystrophy?
- A. Cinacalcet
- B. Bisphosphonates
- C. Calcium restriction
- D. Phosphate binders (Correct Answer)
Explanation: ***Phosphate binders*** - **Phosphate binders** are the initial treatment because **hyperphosphatemia** is the primary driver of secondary hyperparathyroidism in renal disease, triggering parathyroid hormone (PTH) release [1]. - They work by binding dietary phosphate in the gastrointestinal tract, preventing its absorption and thus lowering serum phosphate levels [1]. *Cinacalcet* - **Cinacalcet** is a calcimimetic that increases the sensitivity of calcium-sensing receptors on the parathyroid gland, reducing **PTH secretion** [1]. - It is often used if **phosphate binders** and **vitamin D analogs** are insufficient in controlling PTH, making it a second-line treatment [1]. *Bisphosphonates* - **Bisphosphonates** are used to treat osteoporosis by inhibiting osteoclast activity and reducing bone resorption. - They are generally contraindicated in advanced renal osteodystrophy due to concerns about adynamic bone disease and are not an initial treatment for **secondary hyperparathyroidism**. *Calcium restriction* - While restricting dietary calcium might seem intuitive, **hypocalcemia** is often a problem in renal disease due to impaired vitamin D activation [1]. - Overly restricting calcium can worsen hypocalcemia, which would further stimulate PTH release, thus it is not an initial treatment for **secondary hyperparathyroidism**.
Question 6: Which of the following substances is NOT typically found in gallstones?
- A. Cholesterol
- B. Oxalates (Correct Answer)
- C. Phosphate
- D. Carbonate
Explanation: ***Oxalates*** - Gallstones are primarily composed of **cholesterol**, **bile pigments**, and **calcium salts**, but they do not contain oxalates [1][2][3]. - Oxalates are more commonly associated with **kidney stones**, making this correct. *Carbonate* - Gallstones can contain **calcium carbonate**, particularly in certain types of stones, indicating that this option is incorrect. - These stones are formed in the **gallbladder**, often due to altered bile composition [2]. *Phosphate* - Some gallstones can contain **calcium phosphate**, especially in cases of infection or liver disease, which makes this option unsuitable. - Phosphate can contribute to the formation of **mixed stones** in the gallbladder. *Cholesterol* - In fact, the most common type of gallstone is the **cholesterol stone**, indicating that this option is incorrect [1][3]. - Cholesterol stones form when there is excessive **cholesterol** in the bile, leading to crystallization [3]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Liver and Gallbladder, pp. 882-883. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Liver And Biliary System Disease, pp. 403-404. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Liver and Gallbladder, p. 882.
Question 7: Technetium-99m methylene diphosphonate is structurally similar to
- A. Sodium bicarbonate
- B. Phosphorus
- C. Calcium phosphate (Correct Answer)
- D. Magnesium sulfate
Explanation: ***Calcium phosphate*** - **Technetium-99m methylene diphosphonate (Tc-99m MDP)** is used in bone scans because it structurally mimics **calcium phosphate**, the primary mineral component of bone. - This structural similarity allows Tc-99m MDP to be incorporated into the **hydroxyapatite crystals** present in bone, making it an effective tracer for skeletal imaging. *Sodium bicarbonate* - **Sodium bicarbonate** is a basic salt with a different chemical structure, primarily involved in maintaining pH balance in the body, not bone matrix. - It does not contain phosphate groups or the specific molecular configuration needed to bind to **hydroxyapatite crystals**. *Phosphorus* - While **phosphorus** is a component of calcium phosphate, free phosphorus (as an element) is not structurally similar to Tc-99m MDP. - Tc-99m MDP is a diphosphonate, a complex molecule where the phosphonate groups are critical for bone binding, not just elemental phosphorus. *Magnesium sulfate* - **Magnesium sulfate** is an inorganic salt used for various medical purposes, but it does not have the diphosphonate structure or the affinity for bone mineralization sites that Tc-99m MDP possesses. - Its chemical structure is fundamentally different from that of bone matrix components, preventing its use as a bone imaging agent.
Question 8: All of the following statements regarding stones in the submandibular gland are true except one:
- A. Majority of submandibular stones are radiolucent (Correct Answer)
- B. Patient presents with acute pain and swelling in the region of the submandibular gland
- C. 80% of stones occur in the submandibular gland
- D. The hypoglossal nerve is at risk during submandibular gland excision
Explanation: ***Majority of submandibular stones are radiolucent*** - This statement is **incorrect** because submandibular stones (sialoliths) are typically composed of **calcium phosphate and calcium carbonate**, making them **radiopaque** on plain radiographs. - Approximately **80-90%** of submandibular stones are radiopaque and visible on X-rays. - Only 10-20% are radiolucent, making this the false statement in this "except" question. *80% of stones occur in the submandibular gland* - This statement is **true**; the submandibular gland is the most common site for salivary stones, accounting for **80-92%** of all sialoliths. - This high prevalence is due to Wharton's duct being longer and more tortuous, gravity-dependent positioning, and the alkaline mucinous nature of submandibular saliva. *Patient presents with acute pain and swelling in the region of the submandibular gland* - This is **true** and represents the classic presentation of sialolithiasis. - Pain and swelling typically **worsen with eating** (when salivary flow increases) and may partially subside between meals. - This is often called "mealtime syndrome" or prandial pain. *The hypoglossal nerve is at risk during submandibular gland excision* - This statement is **true**. During submandibular gland excision, the **hypoglossal nerve (CN XII)** runs close to the superior aspect of the gland and can be injured. - Other nerves at risk include the **marginal mandibular branch of the facial nerve** (most commonly injured, causing lower lip weakness) and the **lingual nerve** (causing tongue numbness). - Hypoglossal nerve injury results in tongue deviation toward the affected side and difficulties with speech and swallowing.
Question 9: The function of which of the following is increased by an elevated parathyroid hormone concentration:
- A. Action of osteoblasts only
- B. Osteoclasts (Correct Answer)
- C. Phosphate reabsorptive pathways in the renal tubules
- D. Hepatic formation of 25-hydroxycholecalciferol
Explanation: ***Osteoclasts*** - **Parathyroid hormone (PTH)** primarily acts to increase serum calcium levels by stimulating **osteoclasts**, leading to bone resorption and release of calcium and phosphate into the bloodstream. - While PTH does not directly act on osteoclasts, it binds to receptors on osteoblasts, which then release factors that activate osteoclasts. *Action of osteoblasts only* - PTH indirectly affects **osteoblasts** by binding to their receptors, but this action primarily leads to **RANKL expression**, which then stimulates osteoclast activity, not a direct increase in osteoblastic bone formation. - Chronic elevation of PTH, as seen in primary hyperparathyroidism, can paradoxically lead to a net loss of bone mass due to increased osteoclastic activity. *Phosphate reabsorptive pathways in the renal tubules* - PTH actually **decreases reabsorption of phosphate** in the renal tubules, leading to phosphaturia. This helps to prevent calcium-phosphate precipitation by lowering serum phosphate levels while raising calcium. - This is a key mechanism by which PTH increases serum calcium—by both mobilizing it from bone and reducing its renal excretion, while simultaneously promoting renal phosphate excretion. *Hepatic formation of 25-hydroxycholecalciferol* - The **liver** is responsible for the hydroxylation of vitamin D3 (cholecalciferol) to **25-hydroxycholecalciferol (calcidiol)**, a process that is not directly regulated by PTH. - PTH primarily stimulates the **kidneys** to convert 25-hydroxycholecalciferol to its active form, **1,25-dihydroxyvitamin D (calcitriol)**, which then enhances intestinal calcium absorption.
Question 10: Which of the following is not a treatment option for hypercalcemia?
- A. Strontium (Correct Answer)
- B. Bisphosphonates
- C. Steroids
- D. Phosphate
Explanation: ***Strontium*** - **Strontium ranelate** is primarily used in the treatment of **osteoporosis** to promote bone formation and inhibit bone resorption. - It does not have a recognized role in the acute or long-term management of **hypercalcemia** and could potentially worsen it due to its bone-targeting effects if not carefully managed. *Steroids* - **Glucocorticoids** are effective in treating hypercalcemia associated with **granulomatous diseases** (e.g., sarcoidosis) and certain malignancies (e.g., multiple myeloma) by reducing calcitriol production or tumor burden. - They decrease intestinal calcium absorption and increase renal calcium excretion in conditions where 1,25-dihydroxyvitamin D is elevated. *Bisphosphonates* - **Bisphosphonates** (e.g., zoledronic acid, pamidronate) are potent inhibitors of **osteoclast-mediated bone resorption** and are a cornerstone in the treatment of moderate to severe hypercalcemia, especially due to malignancy. [1] - They are administered intravenously and act by inducing osteoclast apoptosis, thereby reducing the release of calcium from bone. [1] *Phosphate* - **Intravenous phosphate** can be used in severe, resistant hypercalcemia, as it promotes calcium deposition into bone and soft tissues, and forms insoluble calcium-phosphate complexes, thus lowering serum calcium. - Its use is limited due to risks of **ectopic calcification**, renal failure, and hypotension, and it is usually reserved for life-threatening situations where other treatments have failed.
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free